Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan
Status:
Withdrawn
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
Pulmonary Arterial Hypertension (PAH) in the setting of Idiopathic Pulmonary Fibrosis(IPF)is
a risk factor for morbidity and mortality in the peri-lung transplant(LT) setting. Currently
there is no significant data to support the use of pulmonary vasodilators for PAH in the
setting of interstitial lung disease such as IPF. The majority of IPF patients have PAH
either at rest or during exercise. The study hypothesis is that bosentan may improve
morbidity and mortality in the peri-LT setting in both IPF cohorts with either resting or
exercise PAH.
Phase:
Phase 4
Details
Lead Sponsor:
Rajan Saggar University of California, Los Angeles